Swedish biotech Anocca AB has raised $46 million to fund a phase I clinical trial testing its CRISPR-edited T-cell receptor (TCR) immunotherapy targeting KRAS mutations in pancreatic cancer. The lead program, VIDAR-1, is the first nonviral genome-edited TCR cell therapy entering clinical development in Europe, with patient recruitment already underway at multiple European university hospitals. The funding round was led by Mellby Gård and includes several institutional investors. CEO Reagan Jarvis highlighted focus on key milestones and the strategic aim to expand precision cell therapies targeting challenging oncology indications.